Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 36

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies

Matte, Allan·2022·International Journal of Molecular Sciences

Abstract

Despite the advent of many new therapies, therapeutic monoclonal antibodies remain a prominent biologics product, with a market value of billions of dollars annually. A variety of downstream processing technological advances have led to a paradigm shift in how therapeutic antibodies are developed and manufactured. A key driver of change has been the increased adoption of single-use technologies for process development and manufacturing. An early-stage developability assessment of potential lead antibodies, using both in silico and high-throughput experimental approaches, is critical to de-risk development and identify molecules amenable to manufacturing. Both statistical and mechanistic modelling approaches are being increasingly applied to downstream process development, allowing for deeper process understanding of chromatographic unit operations. Given the greater adoption of perfusion processes for antibody production, continuous and semi-continuous downstream processes are being increasingly explored as alternatives to batch processes. As part of the Quality by Design (QbD) paradigm, ever more sophisticated process analytical technologies play a key role in understanding antibody product quality in real-time. We should expect that computational prediction and modelling approaches will continue to be advanced and exploited, given the increasing sophistication and robustness of predictive methods compared to the costs, time, and resources required for experimental studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23158663

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Interrelationship between PAT, continuous DSP, SU technologies and process modelling. For each technology, the primary driver for increasing adaptation is indicated.
Figure 1 Interrelationship between PAT, continuous DSP, SU technologies and process modelling. For each technology, the primary driver for increasing adaptation is indicated.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 64

  1. Vatsa, 2022, In Silico prediction of post-translational modifications in therapeutic antibodies, mAbs, 14, 2023938, 10.1080/19420862.2021.2023938 · DOI
  2. Liu, 2014, In vitro and in vivo modifications of recombinant and human IgG antibodies, mAbs, 6, 1145, 10.4161/mabs.29883 · DOI · Paper page
  3. Kerwin, 2020, Framework mutations of the 10-1074 bnAb increase conformational stability, manufacturability, and stability while preserving full neutralization activity, J. Pharm. Sci., 109, 233, 10.1016/j.xphs.2019.07.009 · doi:10.1016/j.xphs.2019.07.009
  4. Chi, 2021, Pragmatic mAb lead molecule engineering from a developability perspective, Biotechnol. Bioeng., 118, 3733, 10.1002/bit.27802 · DOI
  5. Seeliger, 2015, Boosting antibody developability through rational sequence optimization, mAbs, 7, 505, 10.1080/19420862.2015.1017695 · DOI
  6. Robotham, 2019, Detection and quantification of free sulfhydryls in monoclonal antibodies using maleimide labeling and mass spectrometry, mAbs, 11, 757, 10.1080/19420862.2019.1595307 · DOI
  7. Kim, 2021, Mimicking low pH virus inactivation used in antibody manufacturing proceses: Effect of processing conditions and biophysical properties on antibody aggregation and particle formation, J. Pharm. Sci., 110, 3188, 10.1016/j.xphs.2021.06.002 · DOI
  8. Vogg, 2020, Understanding mAb aggregation during low pH viral inactivation and subsequent neutralization, Biotechnol. Bioeng., 117, 687, 10.1002/bit.27237 · DOI
  9. Saleh, 2021, Modeling the impact of amino acid substitution in a monoclonal antibody on cation exchange chromatography, Biotechnol. Bioeng., 118, 2923, 10.1002/bit.27798 · DOI
  10. Strop, 2012, Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair, J. Mol. Biol., 420, 204, 10.1016/j.jmb.2012.04.020 · DOI
  11. Kittelmann, 2017, Orientation of monoclonal antibodies in ion-exchange chromatography: A predictive quantitative structure-activity relationship modeling approach, J. Chromatogr. A, 1510, 33, 10.1016/j.chroma.2017.06.047 · doi:10.1016/j.chroma.2017.06.047
  12. Gudhka, 2021, Identification of preferred multi-modal ligand-binding regions on IgG1 Fc using nuclear magnetic resonance and molecular dynamics simulations, Biotechnol. Bioeng., 118, 809, 10.1002/bit.27611 · DOI
  13. Lopes, 2015, Single-use in the biopharmaceutical industry: A review of current technology impact, challenges and limitation, Food Bioprod. Process., 93, 98, 10.1016/j.fbp.2013.12.002 · DOI
  14. Barbaroux, 2020, The green imperative. Part One: Life-cycle assessment and sustainability for single-use technologies in the biopharmaceutical industry, BioProcess Int., 18, 12
  15. Jacquemart, 2016, A single-use strategy to enable manufacturing of affordable biologics, Comput. Struct. Biotechnol. J., 14, 309, 10.1016/j.csbj.2016.06.007 · DOI
  16. Hummel, 2019, Modeling the downstream processing of monoclonal antibodies reveals cost advantages for continuous methods for a broad range of manufacturing scales, Biotechnol. J., 14, 1700665, 10.1002/biot.201700665 · DOI
  17. Menzel, 2021, X-ray sterilization of biopharmaceutical manufacturing equipment—Extractables profile of a film material and copolyester Tritan compared to gamma irradiation, Biotechnol. Prog., 38, e3214, 10.1002/btpr.3214 · doi:10.1002/btpr.3214
  18. Gaston, 2018, Evaluation of multilayer film stability by Raman spectroscopy after gamma-irradiation sterilization process, Vib. Spectrosc., 96, 52, 10.1016/j.vibspec.2018.03.002 · doi:10.1016/j.vibspec.2018.03.002
  19. Gaston, 2016, FTIR study of ageing of –irradiated biophamaceutical EVA based film, Polym. Degrad. Stab., 129, 19, 10.1016/j.polymdegradstab.2016.03.040 · doi:10.1016/j.polymdegradstab.2016.03.040
  20. Madsen, 2010, Effect of sterilization techniques on the physiochemical properties of polysulfone hollow fibers, J. Appl. Polym. Sci., 119, 3429, 10.1002/app.32994 · doi:10.1002/app.32994
  21. Gao, 2015, Extractables and leachables issues with the application of single-use technology in the biopharmaceutical industry, J. Chem. Technol. Biotechnol., 91, 289, 10.1002/jctb.4824 · DOI
  22. Matte, A. (2020). Chapter 4—Recent advances in continuous downstream processing of antibodies and related products. Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics, Elsevier.
  23. Khanal, 2021, Developments and opportunities in continuous biopharmaceutical manufacturing, mAbs, 13, e1903664, 10.1080/19420862.2021.1903664 · DOI
  24. Kelly, 2014, Understanding and modeling alternating tangential flow filtration for perfusion cell culture, Biotechnol. Prog., 30, 1291, 10.1002/btpr.1953 · DOI
  25. Madsen, 2022, Single pass tangential flow filtration: Critical operational variables, fouling, and main current applications, Sep. Purif. Technol., 291, 120949, 10.1016/j.seppur.2022.120949 · doi:10.1016/j.seppur.2022.120949
  26. Tan, 2021, Continuous single pass diafiltration with alternating permeate flow direction for high efficiency buffer exchange, J. Memb. Sci., 619, 118695, 10.1016/j.memsci.2020.118695 · doi:10.1016/j.memsci.2020.118695
  27. Fedorenko, 2020, Improved protein A resin for antibody capture in a continuous countercurrent tangential chromatography system, Biotechnol. Boeng., 117, 646, 10.1002/bit.27232 · doi:10.1002/bit.27232
  28. Amritar, 2020, Engineering Staphylococcal Protein A for high-throughput affinity purification of monoclonal antibodies, Biotechnol. Adv., 44, 107632, 10.1016/j.biotechadv.2020.107632 · DOI
  29. Napoleone, 2021, Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells, New Biotechnol., 65, 9, 10.1016/j.nbt.2021.07.002 · DOI
  30. Davis, 2021, Improving mAb capture productivity on batch and continuous processing using nanofiber PrismA adsorbents, J. Biotechnol., 336, 50, 10.1016/j.jbiotec.2021.06.004 · doi:10.1016/j.jbiotec.2021.06.004
  31. Nadar, 2021, Intensified downstream processing of monoclonal antibodies using membrane technology, Biotechnol. J., 16, 2000309, 10.1002/biot.202000309 · DOI
  32. Dods, 2015, Fabricating electrospun cellulose nanofiber adsorbents for ion-exchange chromatography, J. Chromatogr. A, 1376, 74, 10.1016/j.chroma.2014.12.010 · doi:10.1016/j.chroma.2014.12.010
  33. Arnold, 2019, Implementation of fully integrated continuous antibody processing: Effects on productivity and COGm, Biotechnol. J., 14, 1800061, 10.1002/biot.201800061 · DOI
  34. Gillespie, 2019, Continuous in-line virus inactivation for next generation bioprocessing, Biotechnol. J., 14, 1700718, 10.1002/biot.201700718 · DOI
  35. Martins, 2020, Truly continuous low pH viral inactivation for biopharmaceutical process integration, Biotechnol. Bioeng., 117, 1406, 10.1002/bit.27292 · DOI
  36. Kateja, 2021, A novel reactor configuration for continuous virus inactivation, Biochem. Eng. J., 167, 107885, 10.1016/j.bej.2020.107885 · DOI
  37. Pollard, 2017, Lessons learned in building high-throughput process development capabilities, Eng. Life Sci., 16, 93, 10.1002/elsc.201400254 · DOI
  38. Kumar, 2014, Design of experiments applications in bioprocessing: Concepts and approaches, Biotechnol. Prog., 30, 86, 10.1002/btpr.1821 · DOI
  39. Kumar, 2020, Mechanistic modelling of preparative chromatography for biotherapeutics, Ann. Rev. Chem. Biomol. Eng., 11, 235, 10.1146/annurev-chembioeng-102419-125430 · DOI
  40. Babi, 2022, Opportunities and challenges for model utilization in the biopharmaceutical industry: Current versus future state, Curr. Opin. Chem. Eng., 36, 100813, 10.1016/j.coche.2022.100813 · DOI
  41. Hanke, 2014, Purifying biopharmaceuticals: Knowledge-based chromatographic process development, Trends Biotechnol., 22, 210, 10.1016/j.tibtech.2014.02.001 · DOI · Paper page
  42. Benner, 2019, Prediction of lab and manufacturing scale chromatography using min-columns and mechanistic modelling, J. Chromatogr. A, 1593, 54, 10.1016/j.chroma.2019.01.063 · DOI
  43. Schmölder, J., and Kaspereit, M. (2020). A modular framework for the modelling and optimization of advanced chromatographic processes. Processes, 8. · DOI
  44. Leweke, 2018, Chromatography analysis and design toolkit (CADET), Comput. Chem. Eng., 113, 274, 10.1016/j.compchemeng.2018.02.025 · DOI
  45. Rischawy, 2019, Good modelling practise for industrial chromatography: Mechanistic modelling of ion exchange chromatography of a bispecific antibody, Comput. Chem. Eng., 130, 106532, 10.1016/j.compchemeng.2019.106532 · DOI
  46. Briskot, 2019, Prediction uncertainty assessment of chromatography models using Bayesian inference, J. Chromatogr. A, 1587, 101, 10.1016/j.chroma.2018.11.076 · DOI
  47. Shekhawat, 2018, Design of experiments applications in bioprocessing: Chromatography process development using split design of experiments, Biotechnol. Prog., 35, e2730, 10.1002/btpr.2730 · doi:10.1002/btpr.2730
  48. Shekhawat, 2016, Enablers for QbD implementation: Mechanistic modeling for ion-exchange membrane chromatography, J. Memb. Sci., 500, 86, 10.1016/j.memsci.2015.10.063 · doi:10.1016/j.memsci.2015.10.063
  49. Graalfs, 2021, Mechanistic modelling of ligand density variations on anion exchange chromatography, J. Sep. Sci., 44, 805, 10.1002/jssc.202001077 · DOI
  50. Gerzon, 2021, Process analytical technologies—Advances in bioprocess integration and future perspectives, J. Pharm. Biomed. Anal., 207, 114379, 10.1016/j.jpba.2021.114379 · DOI · Paper page
  51. Maruthamuthu, 2020, Process analytical technologies and data analytics for the manufacture of monoclonal antibodies, Trends Biotechnol., 38, 1169, 10.1016/j.tibtech.2020.07.004 · DOI
  52. São Pedro, M.N., Klijn, M.E., Eppink, M.H.M., and Ottens, M. (2021). Process analytical technique (PAT) miniaturization for monoclonal antibody aggregate detection in continuous downstream processing. J. Chem. Technol. Biotechnol. · DOI
  53. Jiang, 2017, Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing, Biotechnol. Bioeng., 114, 2445, 10.1002/bit.26383 · DOI · Paper page
  54. Brestrich, 2018, Selective protein quantification for preparative chromatography using variable pathelength UV/Vis spectroscopy and partial least squares regression, Chem. Engin. Sci., 176, 157, 10.1016/j.ces.2017.10.030 · DOI
  55. Ly, T.T., Ruan, Y., Du, B., Jia, P., and Zhang, H. (2021). Fibre-optic surface plasmon resonance biosensor for monoclonal antibody titer quantification. Biosensors, 11. · DOI
  56. Rolinger, 2021, Comparison of UV- and Raman-based monitoring of the Protein A load phase and evaluation of data fusion by PLS models and CNNs, Biotechnol. Bioeng., 118, 4255, 10.1002/bit.27894 · DOI · Paper page
  57. Yilmaz, 2019, Application of Raman spectroscopy in monoclonal antibody producing continuous systems for downstream process intensification, Biotechnol. Prog., 36, e2947, 10.1002/btpr.2947 · DOI · Paper page
  58. Tiwari, 2018, Use of HPLC as an enabler of process analytical technology in process chromatography, Anal. Chem., 90, 7824, 10.1021/acs.analchem.8b00897 · DOI
  59. Chemmalil, 2020, Online/at-line measurement, analysis and control of product titre and critical product quality attributes (CQAs) during process development, Biotechnol. Bioeng., 117, 3757, 10.1002/bit.27531 · DOI
  60. Gillespie, 2021, Systematic assessment of process analytical technologies for biologics, Biotechnol. Bioeng., 119, 423, 10.1002/bit.27990 · DOI
  61. West, 2021, Process analytical technology for on-line monitoring of quality attributes during single-use ultrafiltration/diafiltration, Biotechnol. Bioeng., 118, 2293, 10.1002/bit.27741 · DOI
  62. Liu, 2022, A fully integrated online platform for real-time monitoring of multiple product quality attributes in biopharmaceutical processes for monoclonal antibody therapeutics, J. Pharm. Sci., 111, 358, 10.1016/j.xphs.2021.09.011 · DOI · Paper page
  63. Rogers, 2018, A view on the importance of “multi attribute method” for measuring purity of biopharmaceuticals and improving overall control strategy, AAPS J., 20, 7, 10.1208/s12248-017-0168-3 · DOI
  64. Jakes, 2021, Rapid analysis of biotherapeutics using Protein A chromatography coupled to Orbitrap mass spectrometry, Anal. Chem., 93, 13505, 10.1021/acs.analchem.1c02365 · DOI

Cited by

See all 36

Metadata

Authors
Matte, A.
Affiliations
Downstream Processing Team, Bioprocess Engineering Department, Human Health Therapeutics Research Center, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC H4P 2R2, Canada
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-08-04
Volume
23
Issue
15
Pages
8663
ISSN
1422-0067
Cited by
36
References
7
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies. https://app.cochat.ai/papers/10.3390/ijms23158663
The paper
Matte, A. (2022). Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23158663

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.